Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transvaginal Botox for Refractory Overactive Bladder
NCT05463822Phase 1Completed
- Sponsor
- Stanford University
- Start
- Jun 2019
- Primary completion
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botulinum toxin type A in overactive bladder (OAB), sponsored by Stanford University. Primary endpoint: Response to the Treatment Benefit Scale (TBS) Questionnaire at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT05463822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463822.